-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Aligos Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2019 to Q3 2025.
- Aligos Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $56K, a 38.5% decline year-over-year.
- Aligos Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $311K, a 13.5% increase year-over-year.
- Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $331K, a 58.4% decline from 2023.
- Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $795K, a 650% increase from 2022.
- Aligos Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $106K, a 25.9% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)